Cephalon, Takeda to promote Provigil in United States

By Elaine Rigoli

Tampa, Fla., June 12 - Cephalon, Inc. and Takeda Pharmaceuticals North America, Inc. announced Monday that the companies have agreed to co-promote Provigil (modafinil) tablets [C-IV] in the United States.

In July, 500 Takeda sales representatives will begin promoting Provigil to primary-care physicians and other appropriate health care professionals in the United States.

At that time, the Cephalon and Takeda sales force co-promoting Provigil will consist of about 900 people.

Modafinil is the only medication in a new class of wake-promoting agents believed to work selectively through the sleep/wake centers to activate the cortex of the brain.

"We are pleased to partner with Cephalon, a dynamic company with a leadership position in the central nervous system market. This relationship is a great fit for both companies," Takeda president Mark Booth said in a news release.

The co-promotion agreement will run for three years with an option to renew annually.

Cephalon is an international biopharmaceutical company based in Frazer, Pa.

Based in Lincolnshire, Ill., Takeda Pharmaceuticals North America is a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. in Japan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.